Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
International journal of biological macromolecules
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/40316102/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- NF-kappa-B inhibitor alpha mediates cancer stemness characteristics in oral squamous cell carcinoma by interacting with cathepsin B. Qin, Tian Xu Zhu, Ying Ying Ng, Wai Hoe Ng, Siew Kit Chek, Min Fey Tang, Kai Dun Humans Mouth Neoplasms Cathepsin B Neoplastic Stem Cells NF-KappaB Inhibitor alpha Cell Line, Tumor Carcinoma, Squamous Cell Cell Proliferation Epithelial-Mesenchymal Transition Cell Movement Animals Gene Expression Regulation, Neoplastic Mice The role of NF-kappa-B inhibitor alpha (IκBα), a well-established negative regulator of the NF-κB signalling pathway in cancer is complex, as evidenced by either promoting or suppressing tumourigenesis, depending on the cancer type, however, in oral squamous cell carcinoma (OSCC) remains unelucidated. Here, for the first time, we report that the elevated levels of both NKFBIA mRNA and IκBα protein in OSCC tumour tissues and OSCC cell lines. Meanwhile, IκBα silencing resulted in the suppression of cell proliferation, migration and invasion in OSCC. In addition, we demonstrated that IκBα can mediate the OSCC stemness and epithelial-mesenchymal transition (EMT) characteristics by directly interacting with cathepsin B (CTSB) and thus, facilitating the progression toward carcinogenesis. More importantly, we identified Psammaplin A (PsA), a natural metabolite derived from marine sponges that would disrupt the IκBα-CTSB interaction via competition, thereby reducing oral spheres formation, cell viability and OSCC tumour growth in vivo, clearly demonstrating its potential as an effective therapeutic agent that specifically targets this oncogenic complex. In summary, we have unveiled a novel mechanism underlying the oncogenic role of IκBα-CTSB complex in OSCC, which may offer the therapeutic potential of targeting this complex with PsA for the treatment of OSCC.